Abstract:Purpose: Early detection and tracking of bulbar dysfunction in amyotrophic lateral sclerosis (ALS) are critical for directing management of the disease. Existing physiological assessments of bulbar dysfunction are often inaccessible and cost-prohibitive for clinical application. Existing clinical assessments are limited. The overall goal of our research is to develop a brief and reliable, clinician-administered assessment tool, the ALS Bulbar Dysfunction Index (ALS-BDI) to evaluate bulbar dysfunction. The aim of this study was to establish content and face validity of the ALS-BDI through item generation and reduction, including item scoring. Methods: The design of the ALS-BDI followed guidelines outlined by the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN). The design stage of the ALS-BDI involved two steps: (Step 1) the generation of candidate items from a literature review of commonly used clinical tools, and selection of items following a review of item reliability and item relevance and expert consensus; (Step 2) the assessment of their content and face validity via online survey feedback from experts ( n = 35). The initial design was followed by a semi-structured cognitive interview with Speech-Language Pathologists ( n = 5) to finalize a testable draft of the instrument. Results: Two drafts of the ALS-BDI were developed. The first draft contained 48 items, after a review of existing clinical tools for their relevance to bulbar dysfunction in ALS. Of the 48 items, 35 items were retained after surveying experts and clinician users for their relevance, feasibility, interpretability, and appropriateness. The second draft of the ALS-BDI contained 37 items, due to one item splitting, based on users cognitive interviews. Conclusions: The ALS-BDI described in this study aims to provide a brief and reliable, clinician-administered assessment tool to evaluate bulbar dysfunction in patients with ALS. Future research will evaluate the psychometric properties of this tool including its reliability, validity, and responsiveness to change over time.

Psychometric properties of the Russian version of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen

The Edinburgh Cognitive And Behavioural Als Screen In A Chinese Amyotrophic Lateral Sclerosis Population

Norwegian version of the Edinburgh cognitive and behavioural ALS screen: Construct validity, internal consistency, inter-rater, and test-retest reliability

Screening instruments of cognition: The relation of the mini-mental state examination to the Edinburgh cognitive and behavioural ALS screen in amyotrophic lateral sclerosis

Development, reliability, validity, and acceptability of the remote administration of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS)

Factors associated with Edinburgh Cognitive and Behavioural ALS Screen (ECAS) alteration at time of diagnosis, in amyotrophic lateral sclerosis

Cognitive impairment in ALS patients and validation of the Spanish version of the ALS-CBS test

ECAS correlation with metabolic alterations on FDG-PET imaging in ALS

Cognitive and Behavioral Impairments in German and Chinese ALS Populations - a Post-Hoc Comparison of National Study Data

Comparison of in-person vs. remote administration of cognitive screening tools for people with ALS

Remote Inference of Cognitive Scores in ALS Patients Using a Picture Description

ALS Cognitive Behavioral Screen-Phone Version (ALS-CBS™-PhV): norms, psychometrics, and diagnostics in an Italian population sample

Repeated cognitive assessments show stable function over time in patients with ALS

Factors Affecting Performance on a Screening Tool in Persons with Amyotrophic Lateral Sclerosis

Validation of the Clinical Assessment Scale for Autoimmune Encephalitis: A Multicenter Study

Face and content validation of the amyotrophic lateral sclerosis—Bulbar dysfunction index (ALS-BDI)

Development and Initial Validation of the Russian Version of the RAADS-14: A Self-Report Questionnaire to Assess Autistic Traits

Cognitive reserve as a modulator of cognitive decline and of behavioral symptoms in patients with amyotrophic lateral sclerosis

Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change

How to detect affect recognition alterations in amyotrophic lateral sclerosis

Assessing the psychometric properties of quality of life measures in individuals with amyotrophic lateral sclerosis: a systematic review